Drug Trial Radar · NCT05687890
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
255
Actual
Start
May 23, 2023
Primary completion
Nov 30, 2024
Study completion Apr 2025
Sponsor
- Lead sponsor
- Biocity Biopharmaceutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of SC0062 capsule in patients with chronic kidney disease (diabetic kidney disease and IgA nephropathy)with albuminuria compared to matching placebo.
Conditions
- Diabetic Kidney Disease
- IgA Nephropathy
Interventions
Placebo of SC0062Drug
Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
SC0062 low doseDrug
Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
SC0062 medium doseDrug
Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
SC0062 high doseDrug
Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in urine albumin creatinine ratio (UACR)Time frame: Week 12
- Changes in urine protein creatinine ratio (UPCR)Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
79 Qingchun Rd.,Shangcheng District
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.